Spring Bank Pharmaceuticals

The Company’s SMNH compounds are small segments of nucleic acids that are designed to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. The Company has designed SB 9200 to selectively activate within infected cells the cellular proteins retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. Spring Bank believes that SB 9200 may play an important role in antiviral therapy by modulating the body’s immune response through its mechanisms of action to fight viral infections.
Type
Public
HQ
Hopkinton, US
Founded
2002
Employees
15 (est)
Spring Bank Pharmaceuticals was founded in 2002 and is headquartered in Hopkinton, US

Spring Bank Pharmaceuticals Locations

Hopkinton, US

Spring Bank Pharmaceuticals Metrics

Spring Bank Pharmaceuticals Summary

Market capitalization

$59.9 M

Closing share price

$7.65
Spring Bank Pharmaceuticals's latest market capitalization is $59.9 M.

Spring Bank Pharmaceuticals Market Value History

Spring Bank Pharmaceuticals News

Spring Bank Pharmaceuticals Company Life

You may also be interested in